Free Trial

Xeris Biopharma (XERS) Earnings Date, Estimates & Call Transcripts

Xeris Biopharma logo
$3.23
+0.01 (+0.31%)
(As of 11/1/2024 ET)

Xeris Biopharma Latest Earnings Summary

Upcoming Q3
Earnings Date
Nov. 8Before Market OpensConfirmed
Actual EPS
(Aug. 8)
-$0.10 Beat By $0.01
Consensus EPS
(Aug. 8)
-$0.11

Xeris Biopharma issued Q2 2024 earnings on August 8, 2024, reporting an EPS of -$0.10, which beat analysts' consensus estimates of -$0.11 by $0.01. Quarterly revenue was reported to be $48.07 million, above the consensus estimate of $46.80 million. With a trailing EPS of -$0.43, Xeris Biopharma's earnings are expected to grow next year, from ($0.40) to ($0.25) per share.

XERS Upcoming Earnings

Xeris Biopharma's next earnings date is scheduled for Friday, November 8, 2024, with a conference call scheduled for at 8:30 AM ET. Interested parties can register for or listen to the call or dial in at 866-813-9403 with passcode "906920".

Get Xeris Biopharma Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xeris Biopharma and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

XERS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

XERS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Xeris Biopharma Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242-$0.14-$0.11-$0.13
Q2 20242-$0.11-$0.11-$0.11
Q3 20242-$0.12-$0.10-$0.11
Q4 20242-$0.08-$0.07-$0.08
FY 20248($0.45)($0.39)($0.42)

Xeris Biopharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
11/8/2024
(Confirmed)
-------  
8/8/2024Q2 2024-$0.11-$0.10+$0.01-$0.10$46.80M$48.07M      
5/9/2024Q1 2024-$0.12-$0.14 -$0.02-$0.14$41.56M$40.64M      
3/6/2024Q4 2023-$0.09-$0.10 -$0.01-$0.10$45.50M$44.39M      
11/9/2023Q3 2023-$0.12-$0.09+$0.03-$0.09$40.93M$48.32M  
8/8/2023Q2 2023-$0.13-$0.14 -$0.01-$0.14$34.84M$38.01M  
5/9/2023Q1 2023-$0.17-$0.12+$0.05-$0.12$30.77M$33.20M  
3/8/2023Q4 2022-$0.16-$0.10+$0.06-$0.10$31.04M$33.14M  
11/9/2022Q3 2022-$0.17-$0.14+$0.03-$0.12$29.12M$29.73M  

Xeris Biopharma Earnings - Frequently Asked Questions

Xeris Biopharma has confirmed that its next quarterly earnings data will be published on Friday, November 8th, 2024. Learn more on XERS's earnings history.

Xeris Biopharma updated its FY 2024 earnings guidance on Thursday, August, 8th. The company issued revenue guidance of $190.0 million-$200.0 million, compared to the consensus revenue estimate of $187.4 million.

In the previous quarter, Xeris Biopharma (NASDAQ:XERS) reported ($0.10) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.11) by $0.01. Learn more on analysts' earnings estimate vs. XERS's actual earnings.

The conference call for Xeris Biopharma's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Xeris Biopharma's latest earnings report can be read online.
Read Transcript

Xeris Biopharma (NASDAQ:XERS) has a recorded annual revenue of $163.91 million.

Xeris Biopharma (NASDAQ:XERS) has a recorded net income of -$62.26 million. XERS has generated -$0.43 earnings per share over the last four quarters.

Xeris Biopharma's earnings are expected to grow from ($0.40) per share to ($0.25) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:XERS) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners